Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models

Martine Latta‐Mahieu(Sanofi (France)), Laurent Pradier(Sanofi (France)), Valérie Roudières(Sanofi (France)), Caroline Hersley(Eli Lilly (United States)), David Riddell(Eli Lilly (United States)), Philippe Goniot(Sanofi (France)), Liesbeth Mertens(Janssen (Belgium)), Pascal Barnéoud(Sanofi (France)), Peter H. Larsen(Lundbeck (Denmark)), Jirong Lu(Eli Lilly (United States)), Tyler McGathey(Eli Lilly (United States)), Gary J. Nabel(National Institutes of Health), Cindy Wintmolders(Janssen (Belgium)), Margaret M. Racke(Eli Lilly (United States)), Sofie Carmans, Nathalie Schussler(Sanofi (France)), Philìppe Bertrand(Sanofi (France)), Nicolas Moindrot(Sanofi (France)), Bradford Elmer(University of California, Davis), Astrid Bottelbergs(Janssen (Belgium)), Véronique Blanc(Sanofi (France)), Paul Ferrari(Sanofi (France)), Bart Roucourt, Alexis Bretteville(Inserm), Zhi‐Yong Yang(Wuhan University), Ling Liu(Children's Hospital of Fudan University), Michael O’Neill(Eli Lilly (United States)), Yaming Wang(Geological Museum of China), Andreas Ebneth(Evotec (Germany)), Véronique Blanchard(Sanofi (France)), Mati Lopez‐Grancha(Sanofi (France)), Emmanuel Brault(Sanofi (France))
Glia
November 14, 2017
Cited by 63


Related Papers